Registry following men with advanced prostate cancer and their treatments over time
Collects long-term health information and blood samples from men with advanced prostate cancer.
Plain-language title generated from the registry record
Registry title: International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Key facts
- Where
- Edmonton, Hamilton, Montreal, Ottawa, Québec, Toronto, and Vancouver, CanadaSee the 7 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for men aged 21 or older with advanced prostate cancer. They must have confirmed prostate adenocarcinoma, and they join a long-term follow-up study.
- Age
- 21 years and older
- Sex
- Men only
- Disease stage
- Advanced prostate cancer (the summary names mHSPC and M0/M1 CRPC). Prostate adenocarcinoma must be confirmed by biopsy, surgery or TURP, or by a biopsy of a metastatic site. Another way in: metastatic disease typical of prostate cancer plus a serum PSA above 20ng/mL at first diagnosis.
Main reasons for not taking part
- A previous second cancer (not prostate) that needs additional systemic therapy, except cancer in situ of the bladder and basal cell skin cancer
Read by machine on 9 November 2026.
Where in Canada
- Cross Cancer Institute, Alberta Health ServicesEdmonton, CanadaTaking people
- Juravinski Cancer CentreHamilton, CanadaTaking people
- Centre Hospitalier de l'Universite de Montreal (CHUM)Montreal, CanadaTaking people
- Ottawa Hospital Cancer CentreOttawa, CanadaTaking people
- CHU de Quebec-Universite LavalQuébec, CanadaTaking people
- Princess Margaret Cancer CentreToronto, CanadaTaking people
- BC Cancer AgencyVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Prostate Cancer Clinical Trials Consortium
- Trial code
- NCT03151629
- Record updated
- 22 May 2026
- Original description
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices.Read full original descriptionShow less
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices.
Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs.
PROMs questionnaires will be collected at enrollment and every three months thereafter.
Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment.
As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
Willing and able to provide written informed consent and privacy authorization for the release of personal health information; NOTE: Privacy authorization may be either included in the informed consent or obtained separately; Males 21 years of age and above; Histological or cytological confirmed prostate adenocarcinoma from TRUS biopsy, radical prostatectomy or TURP Or Documented histopathology or cytopathology of prostate adenocarcinoma from a biopsy of a metastatic site Or Metastatic disease typical of prostate cancer (i.e., involving bone or pelvic lymph nodes or para-aortic lymph nodes) AND a serum concentration of PSA >20ng/mL at the time of initial prostate cancer diagnosis; No previous diagnosis of a second, non-prostate malignancy that requires additional systemic therapy except cancer in situ of bladder and basal cell cancer of skin.